Southern Oncology Specialists has signed an agreement with Deep Lens to use the latter’s AI-based technology and other services for the expansion of its clinical trial offering to patients.

Deep Lens’ AI-based integrated Cloud platform VIPER will be used to automate the process of identifying potentially eligible participants during diagnosis and match them to relevant clinical trials thereafter.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In order to identify the best available clinical trials for the specific diagnosis of a participant, VIPER searches the customised matching engine.

It sends real-time notifications to the entire care team in the narrow enrolment window regarding the eligibility of a patient for available trials, through workflow integration.

VIPER will pre-screen all patients from EMR (OncoEMR) of Southern Oncology Specialists and then merge molecular data feeds from Foundation Medicine, Caris Life Sciences, Guardant Health and Tempus, and all pathology feeds for automatic detection of participants who are qualified for trials.

Deep Lens sales provider vice-president Tyrone Richardson said: “Most oncology clinical trials will fail because they cannot enrol enough patients.

“This is largely due to the increase in precision medicine trials, which frequently have complex eligibility criteria that can be challenging for a site to manage in the often very narrow window of time that is required.

“Deep Lens services are designed to minimise the labour demands of the practice and ensure patients are matched immediately to the right trials, right upon diagnosis.”

Set to bring precision medical trials to Southern Oncology Specialists, the collaboration will also expand its existing research programme.

The comprehensive cancer practice provides oncology and haematology care throughout the Carolinas, the US.